6533b7d9fe1ef96bd126c1c3

RESEARCH PRODUCT

Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study.

Marco GiammancoSalvatore PaternaFilippo M. SarulloSergio FasulloGiuseppe LicataGaspare ParrinelloFrancesca Di GaudioPietro Di PasqualeErsilia Fornaciari

subject

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classNatriuresisDouble-Blind MethodFurosemideHeart rateNatriuretic Peptide BrainNatriuretic peptidemedicineElectric ImpedanceHumansDiureticsBlood urea nitrogenAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionDose-Response Relationship Drugbusiness.industryBioelectrical ImpedanceBrain Natriuretic peptideFurosemideMiddle Agedmedicine.diseaseBrain natriuretic peptideSurgeryHeart failureAnesthesiaDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugFollow-Up Studies

description

OBJECTIVES: The aim of this study was to evaluate the effect of a new treatment for refractory congestive heart failure (CHF) on brain natriuretic peptide (BNP) plasma levels and hydration station. BACKGROUND: The study was aimed at evaluating the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) in refractory CHF patients. METHODS: A total of 94 patients (34 women/60 men) with refractory CHF (age 55 to 80 years) were enrolled. They had to have an ejection fraction <35%, serum creatinine <2 mg/dl, blood urea nitrogen <60 mg/dl, a reduced urinary volume, and a low natriuresis (<500 ml/24 h and <60 mEq/24 h, respectively). Patients were divided (double-blind) into two groups: group 1 (18 women/30 men) received an intravenous furosemide (500 to 1,000 mg) plus HSS twice a day in 30 min. Group 2 (16 women/30 men) received an intravenous bolus of furosemide (500 to 1,000 mg/twice a day) alone, for four to six days. At entry, body weight, blood pressure, heart rate, and laboratory parameters were checked during hospitalization; BNP levels were measured on admission, 6 and 30 days after discharge, while on admission and 6 days after, impedance plethysmography was performed. The HSS group received 120 mmol of Na intake versus 80 mmol in non-HSS group. Fluid intake of 1,000 was given to both groups. RESULTS: The groups were similar for clinical characteristics. A significant increase in daily diuresis and natriuresis was observed in HSS group, p < 0.05. The BNP values showed significant intragroup and intergroup differences, 6 and 30 days after treatment. The patients from the HSS group reached a better hydration state than the non-HSS group after six days. In addition, the HSS group showed a significant reduction in hospitalization time and readmission rate. CONCLUSIONS: Our data show that the HSS group reached dry weight more rapidly, a significantly faster reduction in BNP levels, shorter hospitalization stay, and lower incidence in readmissions in the 30-day study period.

10.1016/j.jacc.2005.01.059https://pubmed.ncbi.nlm.nih.gov/15963400